Supplementary Figure S4 from Model-Informed Clinical Pharmacology Profile of a Novel Fixed-Dose Combination of Nivolumab and Relatlimab in Adult and Adolescent Patients with Solid Tumors

Prediction-Corrected Visual Predictive Check of a) Nivolumab Concentrations versus Actual Time after Previous Dose, and b) Trough Nivolumab concentrations versus actual time after first dose in Adult 1L MEL and Adult Prior-IO MEL at 240 mg Q2W or 480 mg Q4W (relatlimab plus nivolumab), c) concentrations versus actual time after previous dose in pediatric patients (<18 Years), d) Trough concentrations versus actual time after first dose in pediatric patients (<18 years) [Full Nivolumab Population Pharmacokinetic Model]